马林Lemurell

I head up medicinal chemistry for 研究和早期开发 within the 心血管，肾脏和代谢 disease area. In this role I lead a team of over 60 medicinal chemists and oversee the strategic direction and prioritisations of the chemistry in our early disease area pipeline. I also sit on the AstraZeneca Global Chemistry Leaders forum to guide the direction of chemistry for the company.

I have a tremendously strong team so a major part of my role is to guide and support them and remove obstacles, so they can focus on the core project deliverables. I truly enjoy seeing people I work with develop and take on new challenges and succeed.

Over the past six years that I have led this team, 澳门第一赌城在线娱乐已经建立了一个强大的管道, expanded our capabilities into new modalities chemistry and developed an extensive collaboration network.

在我的职业生涯中, I have been the lead chemist or contributing chemist on six drug candidates, 包括13项发明专利. I am particularly proud of the inventorship of a FLAP inhibitor which is currently being evaluated in clinical trials. I led the chemistry from the very start of the programme until late lead optimisation. To present this molecule as a first-time disclosure at the American Chemical Society (ACS) Annual Meeting in 2018 was a special feeling.

I achieved my PhD at 哥德堡 University in organic chemistry, specialising in bio-catalyzed asymmetric oxidation and went on to do my Post Doc at The Scripps Research Institute in California with Nobel Prize laureate Prof. 巴里•沙普利斯. I was in the Sharpless lab when the Cu-catalyzed click reaction was discovered and it has been amazing to witness how it has impacted so many areas of science.